FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 306:1326-1331 June 3, 1982 Number 22 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

Thirteen consecutive patients with primary and secondary pulmonary hypertension who had normal left ventricular function were treated with hydralazine in an effort to reduce pulmonary vascular resistance and clinical symptoms. Despite marked decreases in systemic vascular resistance (40 per cent; P less than 0.001), hydralazine produced only moderate decreases in pulmonary arteriolar resistance (21 per cent), without improving stroke volume or pulmonary-artery pressure. Instead, mean arterial pressure fell markedly (17.5 mm Hg, P less than 0.01) in association with a reflex increase in heart rate (11 beats per minute, P less than 0.01). Four patients became symptomatically hypotensive within 24 hours of the initiation of treatment; two of these four required pressors for circulatory support, and one died. Progressive renal insufficiency developed in one patient, and a symptomatic decrease in systemic arterial oxygen saturation occurred in another; both changes were reversed upon discontinuation of the drug. In conclusion, hydralazine fails to produce consistent hemodynamic and clinical benefits in patients with primary and secondary pulmonary hypertension, and it frequently causes serious adverse reactions.

This article has been cited by other articles:

• Boutet, K., Montani, D., Jais, X., Yaici, A., Sitbon, O., Simonneau, G., Humbert, M. (2008). Review: Therapeutic advances in pulmonary arterial hypertension. Ther Adv Respir Dis 2: 249-265 [Abstract]  
• Liu, C., Balanos, G. M., Fatemian, M., Smith, T. G., Dorrington, K. L., Robbins, P. A. (2008). Effects of hydralazine on the pulmonary vasculature and respiratory control in humans. Exp Physiol 93: 104-114 [Abstract] [Full Text]  
• Widlitz, A., Barst, R.J. (2003). Pulmonary arterial hypertension in children. Eur Respir J 21: 155-176 [Abstract] [Full Text]  
• LEE, J.-H., CHUN, Y.-G., LEE, I.-C., TUDER, R. M., HONG, S.-B., SHIM, T.-S., LIM, C.-M., KOH, Y., KIM, W.-S., KIM, D.-S., KIM, W.-D., LEE, S.-D. (2001). Pathogenic Role of Endothelin 1 in Hemodynamic Dysfunction in Experimental Acute Pulmonary Thromboembolism. Am. J. Respir. Crit. Care Med. 164: 1282-1287 [Abstract] [Full Text]  
• Wensel, R., Opitz, C. F., Ewert, R., Bruch, L., Kleber, F. X. (2000). Effects of Iloprost Inhalation on Exercise Capacity and Ventilatory Efficiency in Patients With Primary Pulmonary Hypertension. Circulation 101: 2388-2392 [Abstract] [Full Text]  
• Peacock, A J (1999). Rare diseases bullet 5: Primary pulmonary hypertension. Thorax 54: 1107-1118 [Full Text]  
• Beck, J R, Mongero, L B, Kroslowitz, R M, Choudhri, A F, Chen, J M, DeRose, J J, Argenziano, M, Smerling, A J, Oz, M C (1999). Inhaled nitric oxide improves hemodynamics in patients with acute pulmonary hypertension after high-risk cardiac surgery. Perfusion 14: 37-42 [Abstract]  
• Fullerton, D. A., Jaggers, J., Wollmering, M. M., Piedalue, F., Grover, F. L., McIntyre, R. C. Jr (1997). Variable Response to Inhaled Nitric Oxide After Cardiac Surgery. Ann. Thorac. Surg. 63: 1251-1256 [Abstract] [Full Text]  
• Fullerton, D. A., Jaggers, J., Piedalue, F., Grover, F. L., McIntyre, R. C. Jr. (1997). EFFECTIVE CONTROL OF REFRACTORY PULMONARY HYPERTENSION AFTER CARDIAC OPERATIONS. J. Thorac. Cardiovasc. Surg. 113: 363-370 [Abstract] [Full Text]  
• Fullerton, D. A., Jones, S. D., Jaggers, J., Piedalue, F., RRT, , Grover, F. L., McIntyre, R. C. Jr. (1996). EFFECTIVE CONTROL OF PULMONARY VASCULAR RESISTANCE WITH INHALED NITRIC OXIDE AFTER CARDIAC OPERATION. J. Thorac. Cardiovasc. Surg. 111: 753-763 [Abstract] [Full Text]  
• Fullerton, D. A., Jones, S. D., Grover, F. L., McIntyre, R. C. Jr (1996). Adenosine Effectively Controls Pulmonary Hypertension After Cardiac Operations. Ann. Thorac. Surg. 61: 1118-1123 [Abstract] [Full Text]  
• Fullerton, D. A., McIntyre, R. C. Jr, Kirson, L. E., St. Cyr, J. A., Whitman, G. J. R., Grover, F. L. (1996). Impact of Respiratory Acid-Base Status in Patients With Pulmonary Hypertension. Ann. Thorac. Surg. 61: 696-701 [Abstract] [Full Text]  
• Alpert, M. A., Concannon, M. D., Mukerji, B., Mukerji, V. (1994). Pharmacotherapy of Chronic Pulmonary Arterial Hypertension: Value and Limitations: Part I: Primary Pulmonary Hypertension. ANGIOLOGY 45: 667-676 [Abstract]  
• Hammond, T. G., Mosesson, M. W. (1989). Fatal Small-Bowel Necrosis and Pulmonary Hypertension in Sickle Cell Disease. Arch Intern Med 149: 447-448 [Abstract]  
• PACKER, M. (1985). Vasodilator Therapy for Primary Pulmonary Hypertension: Limitations and Hazards. ANN INTERN MED 103: 258-270 [Abstract]  
• BROWN, J., ROMAN, M. (1984). Nifedipine and Pulmonary Hypertension. ANN INTERN MED 100: 314-315 [Abstract]  
• RUBIN, L. J., NICOD, P., HILLIS, L. D., FIRTH, B. G. (1983). Treatment of Primary Pulmonary Hypertension with Nifedipine: A Hemodynamic and Scintigraphic Evaluation. ANN INTERN MED 99: 433-438 [Abstract]  
• PEARL, R. G., ROSENTHAL, M. H., SCHROEDER, J. S., ASHTON, J. P. A. (1983). Acute Hemodynamic Effects of Nitroglycerin in Pulmonary Hypertension. ANN INTERN MED 99: 9-13 [Abstract]